Search the Newsreel

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Metagenomi Therapeutics (NASDAQ:MGX) analysts have significantly cut their revenue estimates and increased loss per share forecasts for 2026 following the company's recent quarterly results, which fell short of expectations. The consensus price target has dropped by 13% to US$7.00, reflecting decreased confidence in the …

Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?

Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. …

HC Wainwright Estimates Agenus' Q3 Earnings (NASDAQ:AGEN)

Die Qiagen-Aktie steigt nach Q2-2026-Zahlen und stabiler Prognose

Adagene Releases 1H 2026 Financial Results

Adagene Inc. reported a non-GAAP loss per share of $0.20 and revenue of $1.6M for the first half of 2026, with an adjusted net loss of $14.2M. The clinical-stage biotechnology company, focused on monoclonal antibody drugs for cancer in China, continues its capital-intensive development …

Agenus (NASDAQ: AGEN) awards 1.97M performance-tied stock options to CEO

Agenus Inc. has granted its Chairman and CEO, Armen Garo H, 1.97 million performance-tied stock options with an exercise price of $7.78 per share, expiring in 2036. The options are divided into five equal tranches, each vesting only if the company's stock price reaches …

Adagene H1FY26 net loss widens to $16.4M; misses quarterly EPS estimate

Adagene Inc. reported a widened net loss of $16.4 million for H1FY26, missing quarterly EPS estimates at $(0.20) compared to $(0.10) consensus. Despite the increased loss, revenue from collaboration milestones reached $1.6 million, and a recent capital raise extended the company's cash runway to …

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Agenus Inc. (Nasdaq: AGEN) will present three-year survival data from its Phase 1b C-800-01 study of botensilimab (BOT) and balstilimab (BAL) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the ESMO Gastrointestinal Cancers Congress 2026. The presentation will include updated findings and longer-term …

Agencia Comercial Spirits Signs US$10 Million, Five-Year Networking Deal to Advance Indonesia AI Infrastructure

Agencia Comercial Spirits Ltd. has signed a five-year, US$10 million networking integration services agreement to support its AI computing infrastructure deployment in Indonesia. This deal provides network access and ongoing maintenance for the platform, scaling Agencia’s AI business alongside its whisky operations. However, management …

Agencia Comercial Spirits (AGCC) commits $10M to 5-year AI networking build in Indonesia

Qiagen N.V. : DZ Bank reiterates its Buy rating

DZ Bank has reiterated its "Buy" rating for Qiagen N.V. Analyst Sven Kürten confirmed his positive recommendation for the biotechnology and medical research company. Qiagen N.V. is a global leader in providing chemical products for DNA and RNA manipulation.

These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat

Analysts have significantly cut their revenue and increased their loss per share estimates for Metagenomi Therapeutics, Inc. (NASDAQ:MGX) for 2026. The new consensus predicts a substantial 43% decline in revenue and increased losses per share compared to previous forecasts. This revision suggests a more …

Adagene Inc. (Nasdaq: ADAG) boosts cash to US$127.9M and updates H1 2026 results

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular …

Adagene’s Cancer Trial Results Expected in 1H 2027

Adagene (Nasdaq: ADAG) reported financial results for the first half of 2026, showing $127.9 million in cash and cash equivalents, extending their runway into late 2028. The company highlighted progress with its lead candidate, muzastotug, including a 31% overall response rate in MSS colorectal …

Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing

Goldman Sachs Group Inc. has disclosed a 2.63% voting interest in Qiagen N.V., a Netherlands-based life sciences company, through a filing with the Dutch Authority for the Financial Markets. This stake is composed of both indirect real holdings and potential positions via various derivative …

Ultragenyx reaches settlement on DOJOLVI patent litigation with Esjay Pharma

Ultragenyx Pharmaceutical Inc. has settled patent litigation with Baylor Research Institute and Esjay Pharma regarding its drug DOJOLVI. The agreement grants Esjay a non-exclusive, royalty-free license to market a generic version of DOJOLVI starting January 1, 2033, with a potential extension to July 1, …

Wainwright cuts Agenus stock price target to $25 on higher costs

H.C. Wainwright has lowered its price target for Agenus Inc. (NASDAQ: AGEN) to $25 from $30, while maintaining a Buy rating on the stock, citing higher operating expenses. Despite a recent decline, the stock has seen significant gains over the past six months and …

Agenus (AGEN) director Brian Corvese receives 100,000 stock options at $7.78

Agenus (AGEN) director Brian Corvese was granted 100,000 stock options on August 5, 2026, with an exercise price of $7.78 per share and an expiration date of August 5, 2036. These options, awarded under the company's 2019 Amended and Restated Equity Incentive Plan, will …

Agenus Director Brian Corvese Granted 100,000 Stock Options Under 2019 Equity Incentive Plan

Agenus Inc. director Brian Corvese was granted stock options for 100,000 shares of common stock on August 5, 2026, under the company's 2019 Amended and Restated Equity Incentive Plan. The options have an exercise price of $7.78 per share and an expiration date of …

Form 8K Agenus Inc For: 11 August By Investing.com

This article reports on the filing of a Form 8K by Agenus Inc. for August 11. It's a brief announcement indicating a regulatory filing by the company. The content also includes market data and news headlines not directly related to the Agenus filing.

Agenus appoints Marco Tullio Marcucci to board of directors

Agenus Inc. has appointed Marco Tullio Marcucci as a Class II director to its board, increasing the board size from six to seven members. Marcucci, an attorney specializing in commercial and civil law, will serve until the 2029 annual meeting and will also join …

Agenus Inc (AGEN) awards 50,000 stock options to director Thomas L. Harrison

Agenus Inc. (AGEN) director Thomas L. Harrison was awarded 50,000 stock options on August 5, 2026. These options have an exercise price of $7.78 per share and will expire on August 5, 2036. The options vest over three years, with one-third vesting on the …

Metagenomi Records Wider Q2 Loss As MGX-001 Advanced Toward IND Submission

(RTTNews) - Metagenomi Therapeutics Inc. (MGX), an in vivo genome editing company, on Monday reported second quarter financial results, noting a higher loss owing to increased losses from operations and collaborations. The company specializes in in metagenomics - the study of genetic material from …

Ultragenyx to license generic DOJOLVI to Esjay starting Jan 1, 2033 under settlement

Ultragenyx announced a settlement with Esjay, resolving patent litigation concerning DOJOLVI. Under the agreement, Ultragenyx will grant Esjay a non-exclusive, royalty-free license to market a generic version of DOJOLVI beginning January 1, 2033, with a potential extension to July 1, 2033, pending pediatric exclusivity. …

Wells Fargo cuts Metagenomi stock price target on higher R&D costs

Wells Fargo has lowered its price target for Metagenomi Inc (NASDAQ:MGX) shares to $7.00 from $9.00, while maintaining an Overweight rating, citing higher-than-expected research and development expenses and a larger net loss per share in Q2 2026. Despite the stock trading down 24% year-to-date, …

Porsche SE Aktie – Milliardenverlust Durch Abschreibungen Auf Porsche AG Und Volkswagen AG Iran Supreme Leader Injuries (4KQzkOzqJK)

Unlocking Hidden Value: Why Lagenda Properties Is Deeply Undervalued Amid Strategic Restructuring

Ultragenyx Pharmaceutical Inc. (RARE) Investor Outlook: Nearly 100% Upside Potential According to Analyst Ratings

Ultragenyx Pharmaceutical Inc. (RARE), focused on rare genetic diseases, shows significant upside potential, with analysts setting an average target price of $52.84, nearly double its current $26.80. Despite current negative EPS and significant R&D investments, the company's robust product pipeline, strategic collaborations, and positive …

Exagen at Canaccord Genuity growth conference: turnaround gains pace

Exagen (XGN) showcased its business turnaround at Canaccord Genuity’s 46th Annual Growth Conference, detailing its shift from significant cash burn to near breakeven while expanding its autoimmune testing franchise. The company reported a 57% increase in average selling price to $446, 21% year-over-year revenue …

Metagenomi Therapeutics reports $27.5M loss in Q2 2026

Metagenomi Therapeutics (NASDAQ: MGX) reported a significant net loss of $27.482 million in Q2 2026, widening from the previous year, and missed analyst EPS estimates. The company's collaboration revenue dropped sharply to $(0.257) million from $8.513 million in Q2 2025. Despite these financial setbacks, …

Lagenda Properties Berhad commences an Equity Buyback Plan, under the authorization approved on June 10, 2026.

Metagenomi Therapeutics: Q2 Earnings Snapshot

Form 8K Metagenomi Inc For: 10 August By Investing.com

This article from Investing.com reports that Metagenomi Inc. filed a Form 8K on August 10th. The brief piece includes a stock symbol (MGX) and indicates the stock was trading at 0.00%. The content mainly consists of standard financial market data, including various indices, commodities, …

Metagenomi Therapeutics (MGX) revenue drops as losses widen but cash tops $120M

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour FDA clearance marks QIAGEN's entry into U.S. bloodstream infection testing and establishes the first member of a planned QIAstat-Dx BCID panel …